Breaking the patient-reported outcome code in KRASG12C-mutated colorectal cancer: clinical interpretation of CodeBreaK 300
Mené sur 160 patients atteints d'un cancer colorectal de stade métastatique avec mutation G12C au niveau du gène KRAS et réfractaire à la chimiothérapie, cet essai international de phase III (13 pays) évalue l'intérêt, du point de vue des symptômes déclarés par les patients, d'un traitement combinant sotorasib et panitumumab
Patients with cancer typically want two things: to live longer, and to live better. In the first-line setting, many treatments deliver both overall survival and health-related quality-of-life benefits. Later in the disease course, this dual outcome becomes more elusive, and tradeoffs between duration and quality of life become increasingly personal. The role of the oncologist is to clarify treatment goals, resolve uncertainty, and support patients in choosing care aligned with their values.1
The Lancet Oncology , commentaire, 2025